References – Revlimid

1. Balducci L. Transfusion independence in patients with myelodysplastic syndromes. Cancer 2006;106(10)2087-2094.

2. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic
syndromes. Br J Haematol. 2003 Jan;120(2):187-200.
3. Cazzola M et al. Myelodysplastic Syndromes-Coping with ineffective hematopoiesis. N Engl J Med 2005,352;6.
4. Emerging Treatment Options for Adult MDS: A Clinical Perspective, 2005.
5. Estey EH et al. Treatment and prognosis of the myelodysplastic syndromes. 2006 UpTo Date.
6. Larson R. Myelodysplasia: When to treat and how. Best Practice and Research Clinical Haematology Vol 19, No.2; 293-300, 2006.
7. List A et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New. Eng J Med. 355;14, 2006.
Celgene Corporation. Revlimid package insert. Summit, NJ; 2006.
8. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic
syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65.
9. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57.
10. MDS Foundation. (as of the date of this report this reference had not been provided.)
11. Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Curr Opin Hematol. 2007 Mar;14(2):123-9.
12. Montovani L et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor
and erythropoietin. British Journal of haematology. 2000,109;367-375.
13. National Cancer Institute. Myelodysplastic syndromes (PDQ®): treatment [last modified 03/24/2006].
14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myelodysplastic syndromes – V.1.2007. February 2, 2007.
15. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006 Jun 1;24(16):2576-82.
16. Product Monograph of Aranesp. E-CPS 2006.
17. Product Monograph of Atgam. E-CPS 2006.
18. Product Monograph of Eprex. E-CPS 2006.
19. Product Monograph of Imuran. E-CPS 2006.
20. Product Monograph of Methotrexate. E-CPS 2006.
21. Product Monograph of Neupogen. E-CPS 2006.
22. Product Monograph of Revlimid, dated February 8, 2007.
23. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Exp Hematol. 2007 Apr;35(4 Suppl 1):137-43.
24. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan;81(1):104-30.
25. Stone P. et al. Cancer related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Annals of Oncology 11;971-975, 2000.
26. Thomas ML. Strategies for achieving transfusion independence in myelodysplastic syndromes. European Journal of Oncology Nursing. 2007, 11, 151-158. ■

www.pmprb-cepmb.gc.ca 1 877 861-2350